A. Huitema

发表

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

J. Wanders, J. Beijnen, G. Milano, 2008, British Journal of Cancer.

Clinical Pharmacokinetics of Cyclophosphamide

S. Rodenhuis, J. Beijnen, A. Huitema, 1979, Clinical pharmacokinetics.

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Cancer Chemotherapy and Pharmacology.

Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.

J. Schellens, J. Beijnen, A. Huitema, 2006, Basic & clinical pharmacology & toxicology.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study

J. Schellens, J. Beijnen, R. Mathijssen, 2019, Pharmaceutical Research.

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

S. Linn, J. Schellens, J. Beijnen, 2013, BMC Cancer.

The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance

J. Schellens, J. Severens, A. Huitema, 2013, PharmacoEconomics.

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Jos H. Beijnen, Ron J. Keizer, Alwin D. R. Huitema, 2010, Clinical pharmacokinetics.

A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.

J. Baars, J. Beijnen, A. Huitema, 2009, Cancer biotherapy & radiopharmaceuticals.

Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study

F. van Leth, J. Beijnen, T. Macgregor, 2005, Antiviral therapy.

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

J. Wanders, C. Punt, E. Raymond, 2005, Investigational New Drugs.

Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals

J. Beijnen, A. Huitema, J. Prins, 2005, Clinical pharmacokinetics.

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

J. Nachega, M. Karlsson, P. Denti, 2012, British journal of clinical pharmacology.

CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity

J. Schellens, J. Beijnen, A. Zandvliet, 2007, Clinical Cancer Research.

Therapeutic drug monitoring of oral targeted antineoplastic drugs

W. Huisinga, U. Jaehde, A. Huitema, 2020, European Journal of Clinical Pharmacology.

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

J. Schellens, J. Beijnen, A. Huitema, 2017, Clinical pharmacology and therapeutics.

Tamoxifen for induction of Cre-recombination may confound fibrosis studies in female mice

R. Goldschmeding, A. Huitema, Tri Q. Nguyen, 2017, Journal of Cell Communication and Signaling.

Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia.

H. Caron, T. Kuijpers, A. Huitema, 2009, European journal of cancer.

Safety and pharmacokinetics of plasma- derived MBL substitution in children with chemotherapy-induced neutropenia

T. Kuijpers, A. Huitema, K. Dolman, 2008 .

Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies

J. Wanders, J. Schellens, J. Beijnen, 2011, The AAPS Journal.

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

J. Wanders, J. Schellens, J. Beijnen, 2013, British journal of clinical pharmacology.

Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization in Clinical Oncology

J. Schellens, J. Beijnen, A. Zandvliet, 2008, Clinical pharmacokinetics.

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

W. Figg, A. Huitema, C. Chau, 2021, Molecular Cancer Therapeutics.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and 11C-Erlotinib PET

A. Lammertsma, M. Yaqub, J. Schellens, 2017, The Journal of Nuclear Medicine.

Model‐Based Evaluation of Similarity in Pharmacokinetics of Two Formulations of the Blood‐Derived Plasma Product C1 Esterase Inhibitor

J. Beijnen, A. Huitema, R. Keizer, 2012, Journal of clinical pharmacology.

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar

J. Schellens, J. Beijnen, A. Huitema, 2017, Drug Delivery and Translational Research.

Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring

J. Schellens, J. Beijnen, U. Jaehde, 2012, Clinical Pharmacokinetics.

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

H. Hollema, A. Boddy, D. Richel, 2007, Clinical Cancer Research.

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

J. Schellens, H. Rosing, J. Beijnen, 2007, British journal of clinical pharmacology.

Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors

J. Schellens, J. Beijnen, A. Huitema, 2006, Clinical Cancer Research.

Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

S. Rodenhuis, J. Schellens, J. Beijnen, 2005, British journal of clinical pharmacology.

Integrated Population Pharmacokinetic Model of Both Cyclophosphamide and Thiotepa Suggesting a Mutual Drug–Drug Interaction

S. Rodenhuis, J. Beijnen, A. Huitema, 2004, Journal of Pharmacokinetics and Pharmacodynamics.

Toxicological analysis of azide and cyanide for azide intoxications using gas chromatography

D. D. de Lange, H. Rosing, J. Beijnen, 2020, Basic & clinical pharmacology & toxicology.

Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population

J. Dieleman, J. Beijnen, A. Huitema, 2003, Clinical pharmacokinetics.

Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.

A. Jager, J. Beijnen, R. Mathijssen, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen

W. Zwart, S. Linn, J. Beijnen, 2015, Clinical Pharmacokinetics.

Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological matrices with liquid chromatography mass spectrometry - A tutorial.

A. Huitema, Mohsin El Amrani, E. V. van Maarseveen, 2019, Analytica chimica acta.

Bottom-up sample preparation for the LC-MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices.

H. Rosing, J. Beijnen, A. Huitema, 2020, Bioanalysis.

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

S. Linn, H. Rosing, J. Beijnen, 2020, European Journal of Clinical Pharmacology.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′‐difluorodeoxyuridine and their nucleotides

J. Schellens, H. Rosing, J. Beijnen, 2018, British journal of clinical pharmacology.

Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.

J. Beijnen, A. Huitema, E. V. van Gorp, 2010, British journal of clinical pharmacology.

Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?

F. van Leth, J. Beijnen, T. Macgregor, 2005, Antiviral therapy.

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

P. Ellis, J. von Pawel, D. Talbot, 2007, Clinical Cancer Research.

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

J. Baars, J. Beijnen, A. Huitema, 2010, Human antibodies.

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Cancer Chemotherapy and Pharmacology.

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Pharmacogenetics and genomics.

SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES

J. Schellens, J. Beijnen, A. Zandvliet, 2006, Drug Metabolism and Disposition.

Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.

J. Beijnen, A. Huitema, E. V. van Gorp, 2005, British journal of clinical pharmacology.

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

J. Schellens, J. Beijnen, P. Baas, 2011, Lung cancer.

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose

H. Rosing, J. Beijnen, A. Huitema, 2020, European Journal of Clinical Pharmacology.

Strategies to target drugs to gliomas and CNS metastases of solid tumors

J. Schellens, J. Beijnen, A. Huitema, 2016, Journal of Neurology.

Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review

A. E. Hoetink, A. Huitema, R. Stokroos, 2021, JAC-antimicrobial resistance.

Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution

J. Burger, A. Huitema, A. Mehta, 2017, Annals of Surgical Oncology.

Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.

A. Aalbers, A. Huitema, H. Boot, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Precision Dosing of Targeted Therapies Is Ready for Prime Time

J. Beijnen, A. Sparreboom, R. Mathijssen, 2021, Clinical Cancer Research.

Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients

W. van den Brink, J. Beijnen, A. Huitema, 2018, Journal of clinical psychopharmacology.

Severe Lactic Acidosis in a Diabetic Patient after Ethanol Abuse and Floor Cleaner Intake

J. Schellens, J. Beijnen, A. Huitema, 2014, Basic & clinical pharmacology & toxicology.

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

S. Sundar, J. Beijnen, A. Huitema, 2021, Clinical Pharmacokinetics.

Deep learning body-composition analysis of clinically acquired CT-scans estimates creatinine excretion with high accuracy in patients and healthy individuals

P. Moeskops, A. Huitema, W. Veldhuis, 2022, Scientific Reports.

Hyperhydration with cisplatin does not influence pemetrexed exposure

A. Dingemans, J. Aerts, J. Burgers, 2021, British journal of clinical pharmacology.

Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis

A. Huitema, M. M. van den Heuvel, L. Hilbrands, 2021, Clinical Pharmacokinetics.

Toxicity of pemetrexed during renal impairment explained—Implications for safe treatment

J. Aerts, J. Burgers, R. Mathijssen, 2021, International journal of cancer.

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial

J. Schellens, J. Beijnen, R. Mathijssen, 2017, Clinical Pharmacokinetics.

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS

H. Rosing, J. Beijnen, A. Huitema, 2021, Journal of Pharmaceutical and Biomedical Analysis.

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

S. Rodenhuis, J. Schellens, J. Beijnen, 2009, Cancer Chemotherapy and Pharmacology.

Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function

S. Rodenhuis, J. Schellens, J. Beijnen, 2006, Clinical Cancer Research.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)

M. Lahaye, J. V. van Sandick, A. Aalbers, 2019, BMC Cancer.

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir

J. Beijnen, A. Huitema, D. Pluim, 2021, The Pharmacogenomics Journal.

Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer

H. Rosing, J. Beijnen, A. Huitema, 2019, Prostate Cancer and Prostatic Diseases.

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir

J. Schellens, H. Rosing, J. Beijnen, 2019, Clinical Cancer Research.

Exposure‐Response Assessment of Enzalutamide and Its Major Metabolites in a Real‐World Cohort of Patients with Metastatic Castration‐Resistant Prostate Cancer

H. Rosing, J. Beijnen, A. Bergman, 2019, Pharmacotherapy.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

J. Schellens, H. Rosing, J. Beijnen, 2017, European journal of cancer.

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

J. Schellens, J. Beijnen, A. Huitema, 2013, Gynecologic oncology.

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

J. Wanders, J. Beijnen, G. Milano, 2008, British Journal of Cancer.

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

S. Rodenhuis, J. Schellens, A. Huitema, 2001, British journal of clinical pharmacology.

A phase I and pharmacokinetic study of indisulam in combination with carboplatin

J. Wanders, A. Zandvliet, A. Huitema, 2007, British Journal of Cancer.

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

H. Rosing, C. Berset, H. Hawle, 2016, Haematologica.

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

E. Voest, H. Gelderblom, A. Huitema, 2022, Cancer Chemotherapy and Pharmacology.

Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer

E. Smit, J. Beijnen, J. Burgers, 2021, Drugs.

Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high‐dose chemotherapy

S. Rodenhuis, A. Huitema, M. E. Jonge, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry

A. Huitema, Mohsin El Amrani, E. V. van Maarseveen, 2018, Analytical and Bioanalytical Chemistry.

No pharmacokinetic drug–drug interaction between nevirapine and paclitaxel

J. Schellens, J. Beijnen, A. Huitema, 2005, Anti-cancer drugs.

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

J. Schellens, J. Beijnen, A. Huitema, 2017, Cancer Chemotherapy and Pharmacology.

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820

J. Wanders, J. Schellens, J. Beijnen, 2009, Investigational New Drugs.

Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

A. Huitema, C. van Kesteren, E. V. van Maarseveen, 2019, Blood advances.

ARandomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non ^ Small Cell Lung Cancer

P. Ellis, D. Talbot, C. Norbury, 2007 .

Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.

H. Rosing, J. Beijnen, A. Bergman, 2020, European journal of cancer.

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

J. Beijnen, R. Mathijssen, A. Huitema, 2019, European Journal of Clinical Pharmacology.

Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients

D. Richel, J. Schellens, J. Beijnen, 2007, Clinical pharmacokinetics.

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

S. Rodenhuis, A. Huitema, M. E. Jonge, 2006, British Journal of Cancer.

Sparse Sampling Design for Therapeutic Drug Monitoring of Sequentially Administered Cyclophosphamide, Thiotepa, and Carboplatin (CTC)

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Therapeutic drug monitoring.

Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Cancer Chemotherapy and Pharmacology.

Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens

S. Rodenhuis, J. Beijnen, A. Huitema, 2000, Cancer Chemotherapy and Pharmacology.

Development of a nomogram for the estimation of long‐term adherence to clozapine therapy using neutrophil fluorescence

A. Huitema, W. V. van Solinge, E. Heerdink, 2018, British journal of clinical pharmacology.

Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.

H. Rosing, J. Beijnen, A. Huitema, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women

K. Dooley, P. Denti, A. Huitema, 2018, Clinical Pharmacokinetics.

Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis

J. Yagüe, A. Huitema, R. Sanmartí, 2018, British journal of clinical pharmacology.

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

A. Huitema, C. van Kesteren, E. V. van Maarseveen, 2018, Clinical Pharmacokinetics.

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients

A. Huitema, C. V. van Herpen, R. ter Heine, 2016, Clinical Pharmacokinetics.

Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.

H. Schuitemaker, J. Beijnen, A. Huitema, 2007, AIDS research and human retroviruses.

A semi‐mechanistic model based on glutathione depletion to describe intra‐individual reduction in busulfan clearance

A. Huitema, C. van Kesteren, E. V. van Maarseveen, 2020, British journal of clinical pharmacology.

Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma

A. Huitema, M. Joerger, A. Ferreri, 2012, Leukemia & lymphoma.

E. Voest, H. Gelderblom, A. Huitema, 2022, Cancer Chemotherapy and Pharmacology.

Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

J. Schellens, J. Beijnen, A. Huitema, 2012, Pharmaceutical Research.

A Pharmacokinetic and Pharmacogenetic Study of Efavirenz in Children: Dosing Guidelines can Result in Subtherapeutic Concentrations

J. Beijnen, T. Kuijpers, A. Huitema, 2008, Antiviral therapy.

Modulation of the cytochrome P450–mediated metabolism of ifosfamide by ketoconazole and rifampin

J. Beijnen, A. Huitema, R. Mathôt, 2001, Clinical pharmacology and therapeutics.

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens

J. Schellens, J. Gietema, A. Huitema, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

H. Keizer, J. Schellens, J. Beijnen, 2000, British journal of clinical pharmacology.

Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.

J. Beijnen, R. Mathijssen, P. de Bruijn, 2014, British journal of clinical pharmacology.

Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model

M. Krasowski, A. Huitema, E. V. van Maarseveen, 2019, British journal of clinical pharmacology.

The clinical pharmacology of alkylating agents in high-dose chemotherapy.

S. Rodenhuis, J. Schellens, A. Huitema, 2000, Anti-cancer drugs.

Race Is Not Associated with Nevirapine Pharmacokinetics

J. Beijnen, F. Wit, A. Huitema, 2004, Therapeutic drug monitoring.

Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers

J. Schellens, H. Rosing, J. Beijnen, 2018, British journal of clinical pharmacology.

Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours

H. Rosing, J. Beijnen, A. Huitema, 2021, Drugs in R&D.

Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir

J. Schellens, J. Beijnen, A. Huitema, 2020, Investigational New Drugs.

A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development

J. Schellens, J. Beijnen, A. Huitema, 2019, Journal of clinical pharmacology.

Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer

J. Schellens, J. Beijnen, S. Rottenberg, 2015, The AAPS Journal.

Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2009, Clinical Cancer Research.

Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance

C. Zwaan, A. Huitema, G. Veal, 2021, European journal of cancer.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma.

H. Rosing, J. Beijnen, A. Huitema, 2019, Journal of pharmaceutical and biomedical analysis.

Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia

J. H. van der Lee, F. Groenendaal, J. Dudink, 2019, PloS one.

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies

R. Obach, J. Wanders, J. Schellens, 2010, Investigational New Drugs.

CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis

J. Baars, J. Beijnen, A. Huitema, 2011 .

Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol

U. Fuhr, F. Mayer, U. Jaehde, 2021, Cancers.

Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.

H. Gelderblom, R. Mathijssen, A. Huitema, 2019, Therapeutic drug monitoring.

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.

J. Beijnen, P. D. de Vries, A. Huitema, 2014, The Journal of infectious diseases.

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion

J. Baars, J. Beijnen, A. Huitema, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.

J. Baars, J. Beijnen, A. Huitema, 2011, Human antibodies.

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

J. Schellens, J. Beijnen, A. Huitema, 2017, Clinical Pharmacokinetics.

Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma

Z. Novalić, A. Huitema, Jaap M Middeldorp, 2015, Journal of Cancer Research and Clinical Oncology.

Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer

R. de Bree, P. D. de Jong, A. Huitema, 2022, European Archives of Oto-Rhino-Laryngology.

An easy, fast, and efficient assay for the quantification of peptide Hepcidin-25 in serum and plasma with LC-MS/MS.

A. Huitema, E. Lentjes, K. V. D. van der Elst, 2022, Annals of clinical biochemistry.

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review

J. Beijnen, A. Huitema, T. Dorlo, 2021, Clinical Pharmacokinetics.

Semi-mechanistic Modeling of Hypoxanthine, Xanthine, and Uric Acid Metabolism in Asphyxiated Neonates

S. Vanhatalo, M. Benders, C. Poets, 2022, Clinical Pharmacokinetics.

Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation

D. D. de Lange, A. Huitema, J. Grutters, 2019, Clinical Pharmacokinetics.

Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.

R. Mathijssen, A. Huitema, N. Steeghs, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients

H. Rosing, J. Beijnen, R. Mathijssen, 2020, Clinical Pharmacokinetics.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS

J. Schellens, H. Rosing, J. Beijnen, 2017, Therapeutic drug monitoring.

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients

S. Sleijfer, H. Gelderblom, R. Mathijssen, 2018, Clinical Pharmacokinetics.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

J. Schellens, J. Beijnen, R. Mathijssen, 2016, Clinical Cancer Research.

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

J. Schellens, H. Rosing, J. Beijnen, 2016, Bioanalysis.

Presence of Five Chemotherapeutic Drugs in Breast Milk as a Guide for the Safe Use of Chemotherapy During Breastfeeding: Results From a Case Series

H. Rosing, J. Beijnen, F. Amant, 2022, Clinical pharmacology and therapeutics.

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer

S. Linn, J. Schellens, J. Beijnen, 2019, International journal of cancer.

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels

A. Huitema, D. Katz, N. Steeghs, 2018, BMC cancer.

Solubility and bioavailability improvement of pazopanib hydrochloride

J. Schellens, J. Beijnen, A. Huitema, 2018, International journal of pharmaceutics.

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

J. Schellens, J. Beijnen, R. Mathijssen, 2017, Clinical Pharmacokinetics.

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

P. Moeskops, E. Smit, J. Beijnen, 2022, Pharmaceutical Research.

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer

J. Beijnen, A. Huitema, D. van den Broek, 2022, Clinical and translational science.

Patients With Rare Cancers in the Drug Rediscovery Protocol (DRUP) benefit from Genomics - Guided Treatment Genomics – Guided Treatment of Rare Cancer Patients in DRUP

Henk, E. Cuppen, E. Smit, 2022 .

The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

J. Beijnen, A. Huitema, E. van Werkhoven, 2022, BMC cancer.

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

Y. Bang, J. Schellens, J. Beijnen, 2015, British journal of clinical pharmacology.

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma

H. Rosing, H. Gelderblom, R. Haas, 2021, Cancers.

Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.

J. Beijnen, C. Zwaan, A. Huitema, 2020, Clinical pharmacology and therapeutics.

Individualized Pazopanib Dosing—Response

A. Huitema, N. Steeghs, R. Verheijen, 2016, Clinical Cancer Research.

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662

H. Gelderblom, R. Mathijssen, A. Huitema, 2014, Clinical pharmacology and therapeutics.

Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Therapeutic drug monitoring.

Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma

J. Schellens, J. Beijnen, A. Huitema, 2005, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.

W. M. Smit, J. Schellens, J. Beijnen, 2009, The oncologist.

Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations

A. Huitema, R. Sanmartí, G. Wolbink, 2020, European Journal of Clinical Pharmacology.

Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results

J. Schellens, K. Sikorska, J. V. van Sandick, 2020, The British journal of surgery.

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

J. Schellens, J. Beijnen, A. Zandvliet, 2011, Investigational New Drugs.

Effect of Mycophenolate Mofetil on the Pharmacokinetics of Antiretroviral Drugs and on Intracellular Nucleoside Triphosphate Pools

J. Beijnen, A. Huitema, D. Back, 2004, Clinical pharmacokinetics.

Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study

J. Schellens, J. V. van Sandick, A. Aalbers, 2017, JMIR research protocols.

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

J. Schellens, L. Siu, A. Hansen, 2015, Clinical Cancer Research.

Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing

A. Egberts, L. D. de Vries, F. Groenendaal, 2013, Archives of Disease in Childhood: Fetal and Neonatal Edition.

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine

J. Schellens, H. Rosing, J. Beijnen, 2011, Cancer Chemotherapy and Pharmacology.

Long-term platinum retention after treatment with cisplatin and oxaliplatin

J. Schellens, J. Beijnen, A. Huitema, 2008, BMC clinical pharmacology.

Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours

J. Schellens, H. Rosing, J. Beijnen, 2007, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

J. Beijnen, A. Huitema, G. Sonke, 2022, Clinical pharmacokinetics.

Is age just a number? A population pharmacokinetic study of gemcitabine

J. Beijnen, A. Huitema, N. Steeghs, 2022, Cancer Chemotherapy and Pharmacology.

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”

J. Schellens, J. Beijnen, A. Huitema, 2015, BioMed research international.

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.

J. Beijnen, A. Huitema, A. D. V. de Vries Schultink, 2018, Breast.

Fixed-Dose Enoxaparin After Bariatric Surgery: The Influence of Body Weight on Peak Anti-Xa Levels

A. Huitema, V. Gerdes, J. H. Hooijberg, 2015, Obesity Surgery.

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer

H. Rosing, J. Beijnen, R. Mathijssen, 2021, Clinical pharmacology and therapeutics.

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

J. Schellens, J. Beijnen, A. Huitema, 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Fibrinogen Degradation Speed as a Predictor of Major Bleeding Complications During Catheter Directed Thrombolysis in Patients with Acute Lower Limb Ischaemia.

E. Vonken, G. D. de Borst, A. Huitema, 2021, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review

A. Huitema, B. Oldenburg, H. Fidder, 2019, Digestion.

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

J. Schellens, H. Rosing, J. Beijnen, 2019, CPT: pharmacometrics & systems pharmacology.

The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer

J. Beijnen, A. Huitema, M. Soesan, 2022, Breast Cancer Research and Treatment.

Population Pharmacokinetics of Intracellular 5-Fluorouridine 5′-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine

J. Beijnen, A. Huitema, S. Marchetti, 2021, The AAPS journal.

Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen

F. Groenendaal, T. Egberts, A. Huitema, 2020, British journal of clinical pharmacology.

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

J. Schellens, J. Beijnen, A. Huitema, 2013, British journal of clinical pharmacology.

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study

J. Beijnen, A. Bergman, A. Huitema, 2019, Pharmaceutical Research.

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort

J. Schellens, J. Beijnen, A. Huitema, 2019, Cancer medicine.

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

J. Beijnen, A. Huitema, N. Steeghs, 2022, Frontiers in Oncology.

Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.

J. Beijnen, P. D. de Vries, A. Huitema, 2012, The Journal of antimicrobial chemotherapy.

A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children

C. Zwaan, A. Huitema, G. Kaspers, 2022, Pharmaceutical Research.

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

S. Sundar, J. Beijnen, A. Huitema, 2021, Clinical Pharmacokinetics.

Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib

J. Beijnen, A. Huitema, A. Schinkel, 2020, Clinical Pharmacokinetics.

Sialic Acid-Engineered IL4–10 Fusion Protein is Bioactive and Rapidly Cleared from the Circulation

L. Boon, A. Huitema, C. Hack, 2019, Pharmaceutical Research.

Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer.

J. Bussink, C. Punt, J. Beijnen, 2008, Lung cancer.

Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia

J. H. van der Lee, F. Groenendaal, F. Cools, 2019, Neonatology.

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.

S. Sleijfer, H. Gelderblom, A. Huitema, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

J. Beijnen, R. Mathijssen, A. Huitema, 2019, Pharmaceutical Research.

Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis

A. Huitema, M. Lilien, K. Kraal, 2020, Cancer Chemotherapy and Pharmacology.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

J. Schellens, J. Beijnen, A. Bergman, 2019, Drugs & Aging.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet

J. Schellens, J. Beijnen, A. Huitema, 2013, Drug Delivery and Translational Research.

PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study

J. Beijnen, R. Haas, A. Huitema, 2020, BMJ Open.

Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study

F. van Leth, J. Beijnen, T. Macgregor, 2005, HIV clinical trials.

Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.

J. Beijnen, A. Huitema, F. de Wolf, 2005, Journal of acquired immune deficiency syndromes.

Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs

J. Beijnen, A. Huitema, J. Mulder, 2004, Clinical pharmacokinetics.

Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals

J. Beijnen, A. Huitema, J. Mulder, 2003, Clinical drug investigation.

Cytolytic Virus Activation Therapy for Epstein-Barr Virus–Driven Tumors

Z. Novalić, A. Huitema, Jaap M Middeldorp, 2012, Clinical Cancer Research.

Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.

J. Schellens, A. Huitema, R. Madan, 2019, Journal of pharmaceutical and biomedical analysis.

Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.

S. Rodenhuis, A. Huitema, M. Tibben, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer

H. Rosing, J. Beijnen, A. Huitema, 2019, Investigational New Drugs.

Semi-mechanistic Modeling of Hypoxanthine, Xanthine, and Uric Acid Metabolism in Asphyxiated Neonates

S. Vanhatalo, M. Benders, C. Poets, 2022, Clinical Pharmacokinetics.

Tamoxifen and pregnancy: an absolute contraindication?

F. Amant, A. Huitema, E. Wall, 2019, Breast Cancer Research and Treatment.

Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.

J. Beijnen, H. Klomp, A. Huitema, 2015, Clinical lung cancer.

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib

J. Beijnen, P. Baas, J. Burgers, 2022, Pharmaceutical Research.

Relatively mild symptoms after an olanzapine intoxication in a 2-year-old girl with excessively high serum levels.

J. Beijnen, A. Huitema, J. V. van Woensel, 2011, Journal of child and adolescent psychopharmacology.

Population Pharmacokinetics of Heroin and its Major Metabolites

E. J. Rook, J. M. Ree, J. Beijnen, 2006, Clinical pharmacokinetics.

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs

J. Beijnen, A. Huitema, A. Schinkel, 2022, Pharmaceuticals.

Proton Pump Inhibitor Prophylaxis After Gastric Bypass Does Not Cause Hypomagnesemia

A. Huitema, F. Lauw, T. Boerlage, 2016, Obesity Surgery.

Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review

T. Egberts, A. Huitema, K. Fischer, 2021, Clinical Pharmacokinetics.

Pharmacokinetics and Clinical Efficacy of Phenobarbital in Asphyxiated Newborns Treated with Hypothermia

F. Groenendaal, L. S. Vries, A. Huitema, 2012, Clinical Pharmacokinetics.

Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation

D. D. de Lange, A. Huitema, E. V. van Maarseveen, 2019, Clinical Pharmacokinetics.

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Jos H. Beijnen, Ron J. Keizer, Michel van Benten, 2011, Comput. Methods Programs Biomed..

A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry.

A. Huitema, C. Hack, K. V. D. van der Elst, 2021, Journal of chromatography. A.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real‐world cohort study: does age matter?

J. Schellens, H. Rosing, J. Beijnen, 2018, British journal of clinical pharmacology.

Quinoline antimalarials as investigational drugs for HIV‐1/AIDS: in vitro effects on HIV‐1 replication, HIV‐1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations

S. Rutella, A. Huitema, G. Majori, 2006 .

The boosting of didanosine by allopurinol permits a halving of the didanosine dosage

J. Beijnen, A. Huitema, J. Lange, 2002, AIDS.

Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, A. Huitema, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development of a Framework for Cohort Simulation in Cost-Effectiveness Analyses Using a Multistep Ordinary Differential Equation Solver Algorithm in R

Jan A M Raaijmakers, Johan G C van Hasselt, Gerardus W J Frederix, 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

J. Schellens, H. Rosing, J. Beijnen, 2016, Investigational New Drugs.

The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography–inductively coupled plasma mass spectrometry

J. Schellens, J. Beijnen, A. Huitema, 2008, Anti-cancer drugs.

Drug Interactions Between Antiretroviral Drugs and Comedicated Agents

J. Beijnen, A. Huitema, J. Mulder, 2003, Clinical pharmacokinetics.

Population Pharmacokinetics of Itraconazole in Thai HIV-1-Infected Persons

J. Beijnen, A. Huitema, J. Lange, 2003, Therapeutic drug monitoring.

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

J. Schellens, J. Beijnen, A. Huitema, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence and risk factors for nevirapine-associated rash

J. Beijnen, A. Huitema, R. Heine, 2003, European Journal of Clinical Pharmacology.

Design of a drug‐drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation

J. Schellens, J. Beijnen, A. Huitema, 2014, Pediatric blood & cancer.

Severe Skin Toxicity in Pediatric Oncology Patients Treated with Voriconazole and Concomitant Methotrexate

J. Schellens, A. Huitema, A. S. Schouten-van Meeteren, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.

Jos H Beijnen, Wim van den Brink, Alwin D R Huitema, 2006, Current clinical pharmacology.

Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.

E. J. Rook, W. van den Brink, J. Beijnen, 2006, Basic & clinical pharmacology & toxicology.

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa

S. Rodenhuis, J. Beijnen, A. Huitema, 2009, Cancer Chemotherapy and Pharmacology.

Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice

A. Huitema, L. Hanff, T. Dorlo, 2022, Frontiers in Pharmacology.

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer

J. Beijnen, A. Huitema, J. Schellens, 2006, British Journal of Cancer.

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of analytical toxicology.

Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.

H. Rosing, M. Ellis, A. Huitema, 2016, Anti-cancer drugs.

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.

J. Schellens, J. Beijnen, A. Huitema, 2016, European journal of cancer.

Optimizing drug development of anti‐cancer drugs in children using modelling and simulation

J. Schellens, J. Beijnen, A. Huitema, 2013, British journal of clinical pharmacology.

Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liq

H. Rosing, J. Beijnen, A. Huitema, 2007, Rapid communications in mass spectrometry : RCM.

Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.

H. Rosing, J. Beijnen, A. Huitema, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Population Pharmacokinetics and Pharmacodynamics of Nelfinavir and Its Active Metabolite M8 in HIV-1-Infected Children

J. Beijnen, T. Kuijpers, A. Huitema, 2006, The Pediatric infectious disease journal.

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses

J. Schellens, H. Rosing, J. Beijnen, 2015, Pharmacology research & perspectives.

Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure

J. Beijnen, A. Huitema, E. V. van Gorp, 2008, Antiviral therapy.

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

J. Beijnen, A. Huitema, E. V. van Gorp, 2002, British journal of clinical pharmacology.

Should Non-Nucleoside Reverse Transcriptase Inhibitors be Combined?

J. Beijnen, A. Huitema, B. Kappelhoff, 2005, Drugs in R&D.

The Plasma and Intracellular Steady-State Pharmacokinetics of Lopinavir/Ritonavir in HIV-1-Infected Patients

J. Beijnen, A. Huitema, E. V. van Gorp, 2004, Antiviral therapy.

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

R. Bernards, J. Schellens, H. Rosing, 2020, British Journal of Cancer.

Prospective experimental treatment of colorectal cancer patients based on organoid drug responses

E. Cuppen, E. Voest, F. Weeber, 2021, ESMO open.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

Jos H Beijnen, Alwin D R Huitema, S. Rodenhuis, 2008, Pharmacogenetics and genomics.

Resistance to second-generation androgen receptor antagonists in prostate cancer

W. Figg, A. Huitema, C. Chau, 2021, Nature Reviews Urology.

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose

H. Rosing, J. Beijnen, A. Huitema, 2020, European Journal of Clinical Pharmacology.

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Jos H Beijnen, Alwin D R Huitema, S. Rodenhuis, 2009, British journal of clinical pharmacology.

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma

Annelisa M Cornel, A. Huitema, M. L. Tas, 2021, Cancers.

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy

E. Smit, J. Schellens, J. Beijnen, 2012, Cancer.

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression

J. Schellens, J. Beijnen, A. Zandvliet, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

J. Schellens, H. Rosing, J. Beijnen, 2013, Cancer Chemotherapy and Pharmacology.

Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods

S. Rodenhuis, J. Schellens, J. Beijnen, 2000, Clinical pharmacology and therapeutics.

High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation

D. D. de Lange, A. Huitema, J. Grutters, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes

J. Beijnen, A. Huitema, A. Schinkel, 2019, Cancer Chemotherapy and Pharmacology.

Optimized sample pre-treatment procedure for the simultaneous UPLC-MS/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum.

H. Rosing, J. Beijnen, A. Huitema, 2022, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Persistent neuropathy after treatment with cisplatin and oxaliplatin

J. Schellens, J. Beijnen, A. Huitema, 2009, Acta oncologica.

Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity

J. Koster, J. Laoukili, A. Huitema, 2022, British Journal of Cancer.

A sensitive liquid chromatographic-mass spectrometry method for the quantification of vincristine in whole blood collected with volumetric absorptive microsampling.

H. Rosing, J. Beijnen, A. Huitema, 2023, Journal of pharmaceutical and biomedical analysis.

Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis

J. Ket, A. Huitema, G. Kaspers, 2022, Cancers.

Practical Recommendations for the Manipulation of Kinase Inhibitor Formulations to Age-Appropriate Dosage Forms

A. Huitema, L. Hanff, B. Nuijen, 2022, Pharmaceutics.

Screening for illicit heroin use in patients in a heroin-assisted treatment program.

E. J. Rook, W. van den Brink, J. Beijnen, 2006, Journal of analytical toxicology.

Fixed Dosing of Monoclonal Antibodies in Oncology

J. Schellens, J. Beijnen, E. Voest, 2017, The oncologist.

Pharmacokinetic comparison of two methods of heroin smoking: ‘chasing the dragon’ versus the use of a heating device

E. J. Rook, J. M. Ree, J. Beijnen, 2005, European Neuropsychopharmacology.

Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer

H. Rosing, J. Beijnen, A. Huitema, 2019, Prostate Cancer and Prostatic Diseases.

Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel

W. M. Smit, J. Schellens, J. Beijnen, 2006, Clinical Cancer Research.

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Y. Pommier, W. Figg, A. Huitema, 2020, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients

J. Beijnen, P. D. de Vries, A. Huitema, 2008, Antimicrobial Agents and Chemotherapy.

Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study

A. Zwinderman, Y. Daali, J. Schellens, 2014, Clinical Pharmacokinetics.

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

J. Schellens, J. Beijnen, A. Huitema, 2014, Clinical Pharmacokinetics.

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs

J. Beijnen, A. Huitema, N. Steeghs, 2021, Frontiers in Pharmacology.

Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety.

A. Huitema, F. Leebeek, J. Hofstra, 2012, Clinical immunology.

Lidocaine (Lignocaine) Dosing Regimen Based upon a Population Pharmacokinetic Model for Preterm and Term Neonates with Seizures

F. Groenendaal, T. Egberts, L. S. Vries, 2011, Clinical pharmacokinetics.

An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.

S. Rodenhuis, J. Beijnen, A. Huitema, 2009, Cancer treatment reviews.

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

J. Schellens, J. Beijnen, R. Mathijssen, 2015, British journal of clinical pharmacology.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

S. Sleijfer, J. Schellens, J. Beijnen, 2014, British Journal of Cancer.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome

J. Schellens, J. Beijnen, C. Blank, 2013, European Journal of Clinical Pharmacology.

Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)

P. Nederlof, S. Linn, M. Kok, 2021, Breast Care.

A Phase 1 Dose‐Escalation Study of Low‐Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors

H. Rosing, J. Beijnen, A. Huitema, 2020, Clinical pharmacology in drug development.

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

J. Schellens, H. Rosing, J. Beijnen, 2020, Pharmaceutical Research.

Predictors for Autoimmune Cytopenias after Allogeneic Hematopoietic Cell Transplantation in Children.

A. Huitema, S. Nierkens, J. Boelens, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Mechanism-Based Pharmacokinetic Model for the Cytochrome P450 Drug–Drug Interaction between Cyclophosphamide and ThioTEPA and the Autoinduction of Cyclophosphamide

Jos H. Beijnen, Alwin D. R. Huitema, S. Rodenhuis, 2001, Journal of Pharmacokinetics and Pharmacodynamics.

Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma.

S. Rodenhuis, A. Huitema, M. Tibben, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).

S. Rodenhuis, H. Rosing, J. Beijnen, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF THE STABILIZED CYCLOPHOSPHAMIDE METABOLITE 4-HYDROXYCYCLOPHOSPHAMIDE IN PLASMA AND RED BLOOD CELLS

S. Rodenhuis, J. Beijnen, A. Huitema, 2000 .

Pharmacokinetics of Cyclophosphamide and Thiotepa in a Conventional Fractionated High-Dose Regimen Compared With a Novel Simplified Unfractionated Regimen

S. Rodenhuis, J. Beijnen, A. Huitema, 2009, Therapeutic drug monitoring.

Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

S. Rodenhuis, H. Rosing, J. Beijnen, 2004, Journal of mass spectrometry : JMS.

Sampling technique from central venous catheters proves critical for pharmacokinetic studies.

S. Rodenhuis, A. Huitema, M. Tibben, 1999, Therapeutic drug monitoring.

High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes.

H. Keizer, J. Beijnen, A. Huitema, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2001, Anti-cancer drugs.

Validation of a Therapeutic Drug Monitoring Strategy for Thiotepa in a High-Dose Chemotherapy Regimen

S. Rodenhuis, J. Beijnen, A. Huitema, 2001, Therapeutic drug monitoring.

Innate Immune Recovery Predicts CD4+ T Cell Reconstitution after Hematopoietic Cell Transplantation.

A. Huitema, C. van Kesteren, S. Nierkens, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD4+ T-cell reconstitution predicts Survival Outcomes after acute Graft-versus-Host-Disease; a dual center validation.

A. Huitema, K. Curran, S. Nierkens, 2020, Blood.

Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry

A. Huitema, E. V. van Maarseveen, C. Hack, 2020, The AAPS Journal.

Pharmacological Considerations in Antithymocyte Globulin Exposure Calculation.

A. Huitema, S. Nierkens, M. D. de Witte, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children.

W. Tissing, H. Rosing, C. Zwaan, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

J. Schellens, J. Beijnen, A. Huitema, 2011, International journal of pharmaceutics.

Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice daily

A. Huitema, N. Clumeck, D. Konopnicki, 2005, HIV medicine.

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

R. Bernards, J. Schellens, H. Rosing, 2020, Cancer Chemotherapy and Pharmacology.

Development and validation of a combined liquid chromatography tandem-mass spectrometry assay for the quantification of aprepitant and dexamethasone in human plasma to support pharmacokinetic studies in pediatric patients.

H. Rosing, J. Beijnen, C. Zwaan, 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting

W. Tissing, H. Rosing, A. Huitema, 2022, Supportive Care in Cancer.

Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis.

E. Verheij, A. Huitema, G. Bouma, 2023, Therapeutic drug monitoring.

Impact of age on exposure to oral antiandrogen therapies in clinical practice

J. Schellens, H. Rosing, J. Beijnen, 2018, Prostate Cancer and Prostatic Diseases.

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

E. Cuppen, E. Smit, P. Roepman, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

S. Sleijfer, R. Schilsky, E. Cuppen, 2019, Nature.

Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations

J. Schellens, A. Huitema, A. Imholz, 2018, Journal of clinical pharmacy and therapeutics.

The use of combinations of monoclonal antibodies in clinical oncology.

J. Schellens, J. Beijnen, A. Huitema, 2015, Cancer treatment reviews.

Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas

A. C. Dubbelman, J. Schellens, H. Rosing, 2015, Investigational New Drugs.

Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer

J. Schellens, H. Rosing, J. Beijnen, 2004, Clinical Cancer Research.

The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis

R. de Bree, A. May, A. Huitema, 2020, Journal of clinical medicine.

2OExpanding the use of approved drugs: The CPCT’s Drug Rediscovery Protocol (DRUP)

S. Sleijfer, E. Cuppen, E. Smit, 2017 .

The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study.

R. de Bree, A. Huitema, L. Devriese, 2021, European journal of cancer.

Population pharmacokinetic modelling to support the evaluation of preclinical pharmacokinetic experiments with lorlatinib.

J. Beijnen, A. Huitema, A. Schinkel, 2021, Journal of pharmaceutical sciences.

Toxicity and efficacy of chronomodulated chemotherapy: a systematic review.

L. V. Van Laake, M. Putker, C. Punt, 2022, The Lancet. Oncology.

Pharmacodynamic biomarkers in model-based drug development in oncology.

J. Schellens, J. Beijnen, A. Huitema, 2011, Current clinical pharmacology.

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia

A. Huitema, H. van Tinteren, S. Nierkens, 2021, Blood advances.

Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.

S. Krähenbühl, J. Schellens, A. Huitema, 2012, British journal of clinical pharmacology.

Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation

Jos H. Beijnen, Alwin D. R. Huitema, S. Rodenhuis, 2005, Clinical pharmacokinetics.

Predictive Value of Microdose Pharmacokinetics

Jos H. Beijnen, Alwin D. R. Huitema, H. Rosing, 2019, Clinical Pharmacokinetics.

Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.

A. Huitema, G. Sonke, W. V. van Driel, 2021, Best practice & research. Clinical obstetrics & gynaecology.

High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation

D. D. de Lange, A. Huitema, J. Grutters, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

J. Schellens, J. Beijnen, J. Schornagel, 2006, British journal of clinical pharmacology.

Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis

J. Beijnen, P. D. de Vries, A. Huitema, 2012, Antimicrobial Agents and Chemotherapy.

The preparation of radiolabeled monoclonal antibodies for human use.

J. Beijnen, A. Huitema, L. Tran, 2009, Human antibodies.

Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation

A. Huitema, S. Nierkens, T. Dorlo, 2020, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer

J. Schellens, J. Beijnen, B. Thürlimann, 2016, Cancers.

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

J. Beijnen, J. Schornagel, W. W. ten Bokkel Huinink, 2006, British Journal of Cancer.

Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa.

J. Beijnen, A. Huitema, G. Kaspers, 2023, Therapeutic drug monitoring.

Tyrosine kinase inhibitor levels matter in treating chronic GVHD

A. Huitema, B. Bär, J. Kuball, 2019, Bone Marrow Transplantation.

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial

F. Cavalli, S. Krähenbühl, M. Reni, 2010, British Journal of Cancer.

Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma.

A. Huitema, A. Beishuizen, W. Woessmann, 2022, Haematologica.

Baclofen overdose treated with continuous venovenous hemofiltration

J. Schellens, J. Beijnen, A. Huitema, 2015, European Journal of Clinical Pharmacology.

Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling

Brian R. Phillips, H. Deeg, A. Huitema, 2022, Clinical pharmacology and therapeutics.

Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning.

H. Deeg, A. Huitema, E. V. van Maarseveen, 2020, Journal of proteome research.

Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil.

E. Voest, A. Huitema, H. van Tinteren, 2015, JAMA oncology.

Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates

S. Vanhatalo, M. Benders, C. Poets, 2021, Clinical Pharmacokinetics.

Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.

W. van den Brink, J. Beijnen, A. Zandvliet, 2005, Basic & clinical pharmacology & toxicology.

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of clinical pharmacology.

Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients

A. Huitema, S. Nierkens, J. Boelens, 2021, British journal of clinical pharmacology.

Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: Role of intracellular tenofovir diphosphate levels and review of the literature

P. Lips, A. Huitema, R. ter Heine, 2011, Scandinavian journal of infectious diseases.

Doxorubicin‐induced skeletal muscle atrophy: Elucidating the underlying molecular pathways

A. May, A. Huitema, E. Wall, 2019, Acta physiologica.

Treatment of HIV infection with the CCR5 antagonist maraviroc

A. Huitema, J. Mulder, W. Kromdijk, 2010, Expert opinion on pharmacotherapy.

Severe Cannabinoid Intoxication in A Patient with Non-Small-Cell Lung Cancer

J. Schellens, J. Beijnen, A. Huitema, 2012, Journal of palliative care.

The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

J. Beijnen, A. Huitema, E. van Werkhoven, 2022, BMC Cancer.

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology

J. Schellens, J. Beijnen, A. Huitema, 2018, Clinical Pharmacokinetics.

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials.

J. Beijnen, P. Baas, J. Haanen, 2020, Journal of Geriatric Oncology.

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

J. Schellens, J. Beijnen, A. Huitema, 2014, Therapeutic drug monitoring.

Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

J. Schellens, J. Beijnen, A. Huitema, 2021, Cancer Chemotherapy and Pharmacology.

High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?

A. Huitema, M. Joerger, A. Ferreri, 2011, Leukemia & lymphoma.

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

E. Schuuring, E. Smit, A. Dingemans, 2023, Frontiers in Oncology.

The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients

R. de Bree, T. Egberts, P. D. de Jong, 2022, Journal of cachexia, sarcopenia and muscle.

Reply to: Comments on "Systemic exposure of oxaliplatin and docetaxel in gastric patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy".

J. V. van Sandick, A. Huitema, W. Koemans, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry

J. Schellens, J. Beijnen, A. Huitema, 2007 .

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration‐resistant Prostate Cancer Undergoing Hemodialysis

H. Rosing, J. Beijnen, A. Huitema, 2019, Clinical genitourinary cancer.

Impact of age on exposure to oral antiandrogen therapies in clinical practice

J. Schellens, H. Rosing, J. Beijnen, 2018, Prostate Cancer and Prostatic Diseases.

Model-based treatment optimization of a novel VEGFR inhibitor.

J. Schellens, J. Beijnen, A. Huitema, 2012, British journal of clinical pharmacology.

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients

E. Smit, H. Rosing, J. Beijnen, 2020, Clinical pharmacology and therapeutics.

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies

J. Beijnen, A. Huitema, T. Dorlo, 2022, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.

J. Schellens, J. Beijnen, A. Huitema, 2010, British journal of clinical pharmacology.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet

J. Schellens, J. Beijnen, A. Huitema, 2013, Drug Delivery and Translational Research.

Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors

J. Beijnen, A. Huitema, Maarten van Eijk, 2022, Anti-cancer drugs.

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

J. Schellens, J. Beijnen, M. Karlsson, 2009, Investigational New Drugs.

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

J. Wanders, J. Schellens, J. Beijnen, 2008, British journal of clinical pharmacology.

A Semi-Physiological Population Pharmacokinetic Model Describing the Non-linear Disposition of Indisulam

J. Schellens, J. Beijnen, A. Zandvliet, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

R. Bernards, J. Schellens, H. Rosing, 2020, The oncologist.

Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.

H. Rosing, J. Beijnen, A. Huitema, 2020, European journal of cancer.

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry

J. Schellens, H. Rosing, J. Beijnen, 2016, Therapeutic drug monitoring.

Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.

S. Rodenhuis, J. Beijnen, A. Huitema, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Phase I Study of Afatinib and Selumetinib in Patients with KRASâ•’Mutated Colorectal, Nonâ•’Small Cell Lung, and Pancreatic Cancer

R. Bernards, H. Rosing, J. Beijnen, 2021 .

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

J. Schellens, J. Beijnen, A. Zandvliet, 2012, The AAPS Journal.

Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients

A. Huitema, N. Steeghs, A. Cats, 2017, Clinical Pharmacokinetics.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome

J. Schellens, J. Beijnen, C. Blank, 2013, European Journal of Clinical Pharmacology.

Photophobia in a Patient with High Indinavir Plasma Concentrations

J. Beijnen, A. Huitema, J. Mulder, 2003, Therapeutic Drug Monitoring.

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

J. Beijnen, R. Mathijssen, A. Huitema, 2019, European Journal of Clinical Pharmacology.

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Mats O. Karlsson, Jos H. Beijnen, Ron J. Keizer, 2010, Journal of Pharmacokinetics and Pharmacodynamics.

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

E. Smit, A. Dingemans, R. Mathijssen, 2023, EClinicalMedicine.

Crizotinib-induced fatal fulminant liver failure.

J. Schellens, J. Beijnen, A. Huitema, 2016, Lung cancer.

Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)

R. Kahn, J. Bobes, J. Luykx, 2019, Acta psychiatrica Scandinavica.

Therapeutic Drug Monitoring of Antiretroviral Drugs at Home Using Dried Blood Spots: A Proof-Of-Concept Study

J. Beijnen, A. Huitema, R. ter Heine, 2013, Antiviral Therapy.

Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.

H. Rosing, J. Beijnen, A. Huitema, 2012, The Journal of antimicrobial chemotherapy.

Antineoplastic treatment with crizotinib during pregnancy: a case report

G. Persson, A. Huitema, L. Storgaard, 2018, Acta oncologica.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine

Jos H. Beijnen, J. Schellens, H. Rosing, 2016, Cancer Chemotherapy and Pharmacology.

Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model.

M. Ries, A. Huitema, D. V. van Vuurden, 2023, Journal of controlled release : official journal of the Controlled Release Society.

Tamoxifen for induction of Cre-recombination may confound fibrosis studies in female mice

R. Goldschmeding, A. Huitema, Tri Q. Nguyen, 2017, Journal of cell communication and signaling.

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.

J. Schellens, J. Beijnen, C. Zwaan, 2017, European journal of cancer.

A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

J. Beijnen, A. Huitema, T. Dorlo, 2023, EJNMMI Research.

Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.

S. Rodenhuis, J. Beijnen, A. Huitema, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu‐PSMA‐617 in prostate cancer patients

Steffie M. B. Peters, A. Huitema, J. Nagarajah, 2023, CPT: pharmacometrics & systems pharmacology.

Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling

A. Huitema, J. Hendrikx, B. J. de Wit-van der Veen, 2023, EJNMMI Research.

Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.

R. Bernards, J. Schellens, H. Rosing, 2020 .

Determination of Ifosfamide, 2- and 3-Dechloroethyifosfamide Using Gas Chromatography With Nitrogen-Phosphorus or Mass Spectrometry Detection

J. Beijnen, A. Huitema, J. V. van Putten, 2000, Therapeutic drug monitoring.

Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP)

J. Beijnen, F. Amant, A. Huitema, 2021, Clinical Pharmacokinetics.

An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.

J. Beijnen, A. Huitema, A. Schinkel, 2011, Journal of pharmaceutical sciences.

Incidence of Hematologic Toxicity in Older Adults Treated with Gemcitabine or a Gemcitabine-Containing Regimen in Routine Clinical Practice: A Multicenter Retrospective Cohort Study

J. Schellens, J. Beijnen, A. Huitema, 2014, Drugs & Aging.

Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives

A. Huitema, Mohsin El Amrani, T. Rispens, 2023, Pharmaceutics.

Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

J. Schellens, J. Beijnen, A. Huitema, 2012, Pharmaceutical Research.

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

J. Schellens, J. Beijnen, A. Huitema, 2018, Investigational New Drugs.

The 3rd National Festival & International Congress on Stem Cell & Regenerative Medicine

A. Seifalian, H. Ahmadieh, H. Poustchi, 2018, BioImpacts : BI.

Lethal morphine intoxication in a patient with a sickle cell crisis and renal impairment: Case report and a review of the literature

J. Beijnen, A. Huitema, M. Hillebrand, 2011, Human & experimental toxicology.

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy

J. Schellens, J. Beijnen, A. Huitema, 2014, BioMed research international.

Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle

A. Huitema, Mohsin El Amrani, E. V. van Maarseveen, 2019, Journal of translational autoimmunity.

A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens

J. Beijnen, A. Huitema, T. Dorlo, 2022, Clinical and translational science.

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.

J. Beijnen, M. V. van Vugt, A. Huitema, 2023, Gynecologic oncology.

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

J. Schellens, J. Beijnen, A. Zandvliet, 2012, The AAPS Journal.

Redispensing of expensive oral anticancer medicines: A practical application.

J. Beijnen, A. Huitema, B. Nuijen, 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors

J. Schellens, J. Beijnen, A. Huitema, 2020, Clinical Pharmacokinetics.

Exposure‐response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components

A. Huitema, R. Sanmartí, D. Soy, 2019, British journal of clinical pharmacology.

Three spectroscopic techniques evaluated as a tool to study the effects of iodination of monoclonal antibodies, exemplified by rituximab.

J. Baars, C. Damen, J. Beijnen, 2011, Journal of pharmaceutical and biomedical analysis.

Middle-up quantification of therapeutic monoclonal antibodies in human plasma with two dimensional liquid chromatography high resolution mass spectrometry: Adalimumab as a proof of principle.

A. Huitema, K. V. D. van der Elst, M. van Luin, 2022, Journal of chromatography. A.

Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography-Tandem Mass Spectrometry.

A. Huitema, Mohsin El Amrani, E. V. van Maarseveen, 2019, Therapeutic drug monitoring.

Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations

A. Huitema, R. Sanmartí, G. Wolbink, 2020, European Journal of Clinical Pharmacology.

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.

J. Beijnen, A. Huitema, E. V. van Gorp, 2005, British journal of clinical pharmacology.

A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry

H. Rosing, J. Beijnen, A. Huitema, 2010, Clinical chemistry and laboratory medicine.

Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.

J. Schellens, J. Beijnen, A. Huitema, 2006, Biomedical chromatography : BMC.

Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.

J. Schellens, J. Beijnen, U. Jaehde, 2012, Clinical pharmacokinetics.

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment

J. Schellens, J. Beijnen, A. Huitema, 2016, European Journal of Clinical Pharmacology.

Prediction of Drug Exposure in Critically Ill Encephalopathic Neonates Treated With Therapeutic Hypothermia Based on a Pooled Population Pharmacokinetic Analysis of Seven Drugs and Five Metabolites

Laurent M A Favié, F. Groenendaal, T. Egberts, 2020, Clinical pharmacology and therapeutics.

Ion suppression, reduced long-term robustness and leakage current of the spray voltage during the ionization of trichloroacetic acid; a case study with a methylmalonic acid assay.

A. Huitema, E. Lentjes, K. V. D. van der Elst, 2023, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

J. Schellens, H. Rosing, J. Beijnen, 2018, Pharmaceutical Research.

Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.

J. Beijnen, A. Huitema, E. V. van Gorp, 2011, Bioanalysis.

Anticonvulsant Effectiveness and Hemodynamic Safety of Midazolam in Full-Term Infants Treated with Hypothermia

L. D. de Vries, F. Groenendaal, T. Egberts, 2015, Neonatology.

Concomitant Methotrexate Patients Treated with Voriconazole and Severe Skin Toxicity in Pediatric Oncology

J. Schellens, A. Huitema, N. Eijkelenburg, 2014 .

Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.

H. Rosing, J. Beijnen, A. Huitema, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Stability study of concentrate-solvent mixture & infusion solutions of Jevtana® cabazitaxel for extended multi-dosing

J. Beijnen, A. Huitema, B. Nuijen, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

R. Mathijssen, A. Huitema, N. Steeghs, 2023, Clinical Pharmacokinetics.

Impact of Bariatric Surgery in the Short and Long Term: A Need for Time-Dependent Dosing of Drugs.

A. Huitema, C. van Kesteren, C. Knibbe, 2023, Obesity surgery.

Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review.

A. Huitema, N. Steeghs, Alaa A. Embaby, 2023, Cancer treatment reviews.

Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling

J. Beijnen, A. Huitema, T. Dorlo, 2023, EJNMMI Physics.

Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review

A. Huitema, J. Hendrikx, B. J. de Wit-van der Veen, 2022, Theranostics.

Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations.

Adriaan A Lammertsma, Alwin D R Huitema, A. Lammertsma, 2005, British journal of clinical pharmacology.

The performance of model-based versus rule-based phase I clinical trials in oncology

J. Schellens, J. Beijnen, A. Huitema, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

W. Zwart, L. Natarajan, J. Pierce, 2017, Breast Cancer Research and Treatment.

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women

P. V. van Diest, H. Horlings, W. Zwart, 2021, NPJ breast cancer.

Bioanalysis of HIV protease inhibitors in samples from sanctuary sites.

J. Beijnen, A. Huitema, A. Huitema, 2005, Journal of pharmaceutical and biomedical analysis.

Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT‐enhanced estimate of renal function

P. Moeskops, A. Huitema, M. Rookmaaker, 2023, British Journal of Clinical Pharmacology.

Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes

S. Rodenhuis, J. Beijnen, A. Huitema, 2005, Anti-cancer drugs.

A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO‐101 in Patients With Advanced Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of clinical pharmacology.

Pharmacokinetic boosting of olaparib: a randomised, cross-over study (PROACTIVE-study)

R. Mathijssen, A. Huitema, H. Bloemendal, 2023, European Journal of Cancer.

Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.

J. Beijnen, M. Saag, F. Wit, 2006, AIDS research and human retroviruses.

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

J. Schellens, J. Beijnen, A. Huitema, 2010, Clinical pharmacokinetics.

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients

H. Gelderblom, R. Mathijssen, P. de Bruijn, 2023, Clinical Pharmacokinetics.

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

J. Schellens, J. Beijnen, A. Huitema, 2014, Therapeutic drug monitoring.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

J. Schellens, H. Rosing, J. Beijnen, 2018, Biomedical chromatography : BMC.

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

J. Nachega, M. Karlsson, P. Denti, 2012, British Journal of Clinical Pharmacology.

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Pharmacogenetics and genomics.

H. Rosing, H. Hawle, A. Huitema, 2016, Haematologica.

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial

A. Dingemans, J. Burgers, R. Mathijssen, 2022, Cancer Chemotherapy and Pharmacology.

Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof‐of‐concept study

J. Burgers, A. Huitema, R. ter Heine, 2022, British journal of clinical pharmacology.

Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

H. Rosing, J. Beijnen, A. Huitema, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Current problems and possible solutions in the treatment of nasopharyngeal carcinoma in Indonesia

Z. Novalić, A. Huitema, Jaap M Middeldorp, 2013 .

Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy

S. Rodenhuis, O. Dalesio, J. Beijnen, 2002, Bone Marrow Transplantation.

Correction to: Therapeutic drug monitoring of oral targeted antineoplastic drugs

W. Huisinga, U. Jaehde, A. Huitema, 2020, European Journal of Clinical Pharmacology.

Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients

J. Beijnen, P. D. de Vries, A. Huitema, 2008, Antimicrobial Agents and Chemotherapy.

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV‐care

J. Beijnen, A. Huitema, A. Boer, 2004, Journal of clinical pharmacy and therapeutics.

Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study

J. Schellens, J. V. van Sandick, A. Aalbers, 2017, JMIR research protocols.

Early Estimation of Renal Function After Transplantation to Enable Appropriate Dosing of Critical Drugs: Retrospective Analysis of 103 Patients in a Single Center

A. V. van Zuilen, A. Huitema, M. Rookmaaker, 2020, Clinical Pharmacokinetics.

Lidocaine (Lignocaine) Dosing Regimen Based upon a Population Pharmacokinetic Model for Preterm and Term Neonates with Seizures

F. Groenendaal, T. Egberts, A. Huitema, 2011, Clinical pharmacokinetics.

The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab

J. Baars, J. Beijnen, A. Huitema, 2011 .

Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

J. Schellens, J. Tabernero, M. Alsina, 2016 .

M. Lahaye, A. Aalbers, A. Huitema, 2019, BMC Cancer.